
Rheumatoid Arthritis - Pipeline Insight, 2024
Description
Rheumatoid Arthritis - Pipeline Insight, 2024
DelveInsight’s, “Rheumatoid Arthritis - Pipeline Insight, 2024” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Rheumatoid Arthritis: Overview
Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints. The disorder does not stay constrained to joints of hands and legs. It has the power to influence any part of the body that involves synovial fluid; approximately 30% of the people who suffer from RA experience pain and other remarkable signs and symptoms that do not involve joints, including heart, kidneys, salivary glands, nerve tissues, skin, eyes bone marrow, blood vessels. The exact cause of RA is still not known.
Most of the signs and symptoms of RA are vague and reoccur every time after departing. Few symptoms could be evident enough in the early stages for a person to go for the confirmatory diagnosis. Still, the symptoms in the initial days overlap with several other normal health-related issues. Due to which a person does not move forward with the diagnostic procedure.
Clinically, RA patients typically present with a recent onset of tender and swollen joints, morning joint stiffness, generalized sickness symptoms. Timely and precise diagnosis is of high importance in RA treatment since early diagnosis can arrest irreparable joint damage and disability in up to 90% of RA patient’s disease in many patients, thereby preventing or substantially slowing disease progression. Typically, RA is diagnosed by a combination of patient’s symptoms, results of doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.
DMARDs are a group of drugs that have been shown to affect the underlying cause of RA by damping down the over-activity of the immune system, which helps ease pain, swelling, and stiffness, and prevent changes occurring within the joint. JAK inhibitors are a new type of medicine available for adults with severe rheumatoid arthritis. Advances in chemical engineering have made it possible to produce these called ‘small molecule’ drugs—chemicals that are highly specific for blocking molecules that have been identified within cells that cause chronic inflammation. To date, the US FDA has approved three JAK inhibitors for the treatment of RA. These are: Tofacitinib (Xeljanz), Baricitinib (Olumiant), Upadacitinib (Rinvoq).
“Rheumatoid Arthritis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.
This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rheumatoid Arthritis Emerging Drugs
- SM03: SinoMab
This has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. As a potential global first-in-target mAb for the treatment of RA, SM03 is a recombinant immunoglobulin IgG1 monoclonal antibody. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Rheumatoid Arthritis.
- SHR0302: Jiangsu Hengrui Medicine
SHR0302 has an anti-proliferative and anti-inflammatory effect. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and eczema. The drug is currently being evaluated in Phase III stage of clinical trial to treat Rheumatoid Arthritis.
- RC18: RemeGen
- Zalunfiban: CeleCor Therapeutics
Zalunfiban targets platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, to inhibit all platelet activators and can, under some conditions, promote recanalization of occluded arteries. In contrast, other antiplatelet medications, including P2Y12 inhibitors and aspirin, inhibit only one platelet activator and have not been demonstrated to promote recanalization.
Further, due to decreased gastrointestinal absorption, oral P2Y12 inhibitors given before the procedure to open the artery do not act rapidly or reliably enough in STEMI patients during the crucial early minutes of a heart attack and have not demonstrated a clinical benefit to date. It is currently being investigated in Phase III stage of development for the treatment of Rheumatoid Arthritis.
- ABBV-3373: Abbvie
- Dazodalibep: Horizon Therapeutics
- AP1189: Synact Pharma
- Dekavil: Philogen
IL-10 plays a potential role in human diseases: In rheumatoid arthritis, the addition of IL-10 to synovial membrane cultures can decrease IL-1β and TNF-α expression. Similarly, blocking endogenous IL-10 can cause a 2- to 3-fold increase in the expression of these proinflammatory cytokines. Moreover, activating the IL-10 pathway has shown promise as a therapeutic strategy in preclinical mouse models.
Further product details are provided in the report……..
Rheumatoid Arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Rheumatoid Arthritis
Phases
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Rheumatoid Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.
Rheumatoid Arthritis Report Insights
- Rheumatoid Arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rheumatoid Arthritis drugs?
- How many Rheumatoid Arthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rheumatoid Arthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Yuyu Pharma, Inc.
- Worg Pharmaceuticals
- Vyne Therapeutics
- Vaccinex Inc.
- Tiziana Life Sciences
- Teijin Pharma
- Taiho Pharmaceutical
- Synermore Biologics Co., Ltd.
- Synact Pharma
- Sorrento Therapeutics
- Sonoma Biotherapeutics
- SinoMab Bioscience Ltd
- Silo Pharma
- SFA Therapeutics
- Servatus Biopharmaceuticals
- SciRhom
- R-Pharm
- Rottapharm Biotech
- ROS Therapeutics
- RheumaGen
- Revolo Biotherapeutics
- RemeGen
- Regen BioPharma Inc.
- PrecisionLife
- Philogen
- Pfizer
- Oryn Therapeutics
- Nurix
- NovImmune
- Novartis
- Neutrolis Therapeutics
- MyMD Pharmaceuticals
- Modern Biosciences
- Minghui Pharmaceutical Pty Ltd
- MetrioPharm
- Mesoblast
- Lysatpharma GmbH
- Lynk Pharmaceuticals
- Landos Biopharma
- Kymera Therapeutics
- Kolon TissueGene
- KLUS Pharma
- Kiniksa Pharmaceuticals, Ltd.
- Kangstem Biotech
- Jubilant Therapeutics
- Jiangsu Hengrui Medicine
- Janssen Research & Development
- Intrinsic Medicine
- Innocare Pharma Australia Pty Ltd
- Immutep Limited
- Imcyse
- I-Mab Biopharma Co. Ltd.
- Iltoo Pharma
- IGM Biosciences, Inc.
- ICMBIO
- Ichnos Sciences
- Hutchison MediPharma
- Horizon Therapeutics plc
- Hope Biosciences
- Hanlim Pharm
- Gilead Sciences
- Genosco
- Galmed Pharmaceuticals
- Galapagos NV
- Fresh Tracks Therapeutics, Inc.
- Fountain Biopharma Inc.
- f5 Therapeutics
- Evelo Biosciences
- Endpoint Health
- Eli Lilly and Company
- Draconis Pharma
- Cyxone
- CV6 Therapeutics
- Chong Kun Dang Pharmaceutical
- Celltex Therapeutics
- Carna Biosciences
- Cabaletta Bio
- BTB Pharma
- Bristol-Myers Squibb
- Boryung Pharmaceutical Co., Ltd
- Biozeus
- Beijing Baylx Biotech
- Bayer
- Bagi Biosciences
- AstraZeneca
- Arthrogen
- Applied Molecular Transport
- YY-3411
- Research programme
- VYN 201
- VX5/5261
- Foralumab
- TCK 276
- TAS5315
- SYN060
- AP1189
- Sofusa anti-TNF
- SBT 77 7101
- SM03
- SPU-21
- SFA002
- SVT 6A4710
- Research programme: anti-iRhom2 monoclonal antibodies
- Olokizumab
- CR 6086
- Trexior
- Research Programme: HLA Gene-Editing
- IRL 201805
- RC18
- Research Programme: small molecule
- Research programme: Rheumatoid arthritis
- Dekavil
- PF-06651600/ PF-6650833/ tofacitinib
- PF-06650833
- PF-06835375
- ORTD-1
- NX-5948
- NI-0101
- VAY736
- CFZ-533
- NTR-441
- MYMD-1
- MBS2320
- MH004
- MP 1032
- MPC-300-IV
- LPRA-01
- LNK01001
- LABP-104
- LABP-69
- KT-474
- Invossa
- A223
- KPL-404
- FURESTEM-RA
- JBI-1044
- SHR0302
- Nipocalimab
- JNJ-4703
- OM001
- ICP-022
- IMP 761
- Research programme: rheumatoid arthritis therapeutics
- TJ003234
- Interleukin 2
- IgM Antibodies
- ICM-203-R
- ISB-830
- HMPL-523
- Dazodalibep
- HB-adMSC
- HL237
- GS-5718
- SKI-O-703
- Amilo 5MER
- GLPG3970
- '4399
- FRTX-02
- FB704A
- Research programme: Autoimmune disorder therapeutics
- EDP1815
- EP004
- LY3462817
- Research Programme: EP4 Program receptor antagonist
- Rabeximod
- CV6 1271
- CKD-506
- CKD-374
- Autologous Adipose-derived Stem Cells
- AS 0871
- CABA-201
- BTB003
- Varicella Zoster Vaccine
- Nivolumab
Table of Contents
250 Pages
- Introduction
- Executive Summary
- Rheumatoid Arthritis : Overview
- Introduction
- Types of RA
- Pathogenesis
- Risk factors
- Diagnosis
- Signs and Symptoms
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- SM03: SinoMab
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ABBV-3373: Abbvie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- SVT 6A4710: Servatus Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SYN060: Synermore Biologics Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- CABA-201: Cabaletta Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Rheumatoid Arthritis - Collaborations Assessment- Licensing / Partnering / Funding
- Rheumatoid Arthritis - Unmet Needs
- Rheumatoid Arthritis - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.